Literature DB >> 18201867

Ectopic pregnancy in a breast cancer patient receiving trastuzumab.

Paul Berveiller1, Olivier Mir, Eric Sauvanet, Eric-Charles Antoine, François Goldwasser.   

Abstract

Cervico-isthmic pregnancy is a rare form of ectopic pregnancy with a poor obstetrical prognosis, whose mechanism remains unclear. Preclinical data indicate that HER-2 plays a major role in embryo implantation. We report a case of cervico-isthmic pregnancy occurring during treatment with trastuzumab (Herceptin, a monoclonal antibody to HER-2). A 43-year-old woman presented with abnormal vaginal bleeding, while she was receiving trastuzumab for the last 14 months as an adjuvant therapy for a node-positive, HER-2 positive breast cancer. The diagnosis of evolutive cervico-isthmic pregnancy was confirmed by iterative ultrasonographic examinations. Given the poor obstetrical prognosis, the patient underwent voluntary abortion. The use of trastuzumab during pregnancy is still poorly documented, and its safety is not yet established. Given the importance of HER-2 in embryo implantation and fetal development, its putative role in this abnormal embryo implantation should be discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18201867     DOI: 10.1016/j.reprotox.2007.11.004

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  3 in total

1.  Chemotherapy for breast cancer in pregnancy: evidence and guidance for oncologists.

Authors:  Sophie E McGrath; Alistair Ring
Journal:  Ther Adv Med Oncol       Date:  2011-03       Impact factor: 8.168

2.  Breast cancer and pregnancy: how safe is trastuzumab?

Authors:  Hatem A Azim; Fedro A Peccatori; Sarah J Liptrott; Chiara Catania; Aron Goldhirsch
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

3.  Trastuzumab administration during pregnancy: an update.

Authors:  Angeliki Andrikopoulou; Kleoniki Apostolidou; Spyridoula Chatzinikolaou; Garyfalia Bletsa; Eleni Zografos; Meletios-Athanasios Dimopoulos; Flora Zagouri
Journal:  BMC Cancer       Date:  2021-04-26       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.